|
2023
|
Invention
|
Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells. Provided he... |
|
2022
|
Invention
|
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy. ccc hete... |
|
|
Invention
|
Interleukin-2 receptor βeta (il-2rβ) binding polypeptides. inter alia, inter alia, de novo IL-2Rβ... |
|
2021
|
Invention
|
De novo protein decoys of angiotensin-converting enzyme 2 (ace2). Provided herein are de novo pro... |
|
|
Invention
|
Interleukin-2 receptor beta (il-2rb) binding polypeptides.
The present invention is related to, ... |
|
2020
|
Invention
|
Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor.
The prese... |
|
|
Invention
|
Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor. The presen... |
|
|
Invention
|
Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor. inter alia... |
|
|
Invention
|
Methods of administration of il-2 receptor agonists.
The present invention provides, inter alia,... |
|
|
Invention
|
Methods of administration of il-2 receptor agonists. The present invention provides, inter alia, ... |
|
2019
|
P/S
|
Medical preparations; pharmaceutical preparations; Medical preparations for the treatment of infl... |
|
|
P/S
|
Medical preparations for the treatment of inflammatory,
autoimmune and infectious diseases and f... |
|
|
P/S
|
Medical preparations for the treatment and use in oncology; pharmaceutical preparations and subst... |
|
2018
|
Invention
|
Ship1 modulators and methods related thereto. Compounds of formula (I):
where
8 are defined h... |
|
2014
|
Invention
|
Ship1 modulators and methods related thereto. 8 are defined herein, or pharmaceutically acceptabl... |
